Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologyNeuro-OncologyDiseaseGestational Trophoblastic NeoplasiaMalignant MeningitisSubgroupICD10C79.3D39.-D39.2MeSHGestational Trophoblastic DiseaseMeningeal CarcinomatosisSequenceCISP20/ETOP100, GTN, Ind. (PID1608) -|- EMA/CO (ETOP100/DCTN0.5/MTRX1000/VNCR1.0/CYCL600) (PID1610) or (PID1607) with (PID1616)ChemotherapyChemo-substanceMethotrexateChemo-substanceMethotrexateChemo-substanceMethotrexateChemo-substanceMethotrexateNo. Substances1 RadiotherapySupportive therapySupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 10g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityLeukopeniaMucositisNeuropathyThrombocytopenia below 50 000/µl only studiesPublicationAuthorAlifrangis CDiseaseTrophoblastäre gestationale Neoplasie, high-risk (FIGO score 7 oder höher)OriginImperial College Academic Science National Health Service Trust, London, United KingdomProtocols in Revision 1 protocol foundProtocols under revision.Methotrexate 12.5, Gestational Trophoblastic Neoplasia (PID1616 V1.1)
